Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
Elanco Animal Health (NYSE:ELAN) announced major milestones for two key pet health products. Credelio Quattro achieved blockbuster status with $100 million in net sales in less than eight months, becoming Elanco's fastest pet health blockbuster. The product captured 14% dollar share in broad-spectrum sales at U.S. veterinary clinics in June.
The company also announced the launch of Zenrelia, a once-daily oral JAK inhibitor for treating allergic and atopic dermatitis in dogs, in the EU and Great Britain. The product has already treated over half a million dogs globally and demonstrated non-inferiority versus Apoquel in a study of 338 dogs across 25 sites.
Elanco Animal Health (NYSE:ELAN) ha annunciato traguardi importanti per due prodotti chiave per la salute degli animali domestici. Credelio Quattro ha raggiunto lo status di blockbuster con 100 milioni di dollari di vendite nette in meno di otto mesi, diventando il blockbuster per la salute degli animali domestici più rapido di Elanco. Il prodotto ha ottenuto una quota del 14% in termini di valore nelle vendite a spettro ampio nelle cliniche veterinarie statunitensi a giugno.
L'azienda ha inoltre lanciato Zenrelia, un inibitore JAK orale somministrato una volta al giorno per il trattamento della dermatite allergica e atopica nei cani, nell'UE e in Gran Bretagna. Il prodotto ha già trattato oltre mezzo milione di cani a livello globale e ha dimostrato non inferiorità rispetto ad Apoquel in uno studio su 338 cani in 25 siti.
Elanco Animal Health (NYSE:ELAN) anunció hitos importantes para dos productos clave de salud para mascotas. Credelio Quattro alcanzó el estatus de blockbuster con 100 millones de dólares en ventas netas en menos de ocho meses, convirtiéndose en el blockbuster más rápido de Elanco en salud de mascotas. El producto logró una participación en valor del 14% en ventas de amplio espectro en clínicas veterinarias de EE. UU. en junio.
La compañía también anunció el lanzamiento de Zenrelia, un inhibidor JAK oral de administración diaria para el tratamiento de dermatitis alérgica y atópica en perros, en la UE y Gran Bretaña. El producto ya ha tratado a más de medio millón de perros a nivel mundial y demostró no inferioridad frente a Apoquel en un estudio de 338 perros en 25 centros.
Elanco Animal Health (NYSE:ELAN)은 반려동물 건강용 핵심 제품 두 가지에 대해 주요 성과를 발표했습니다. Credelio Quattro는 8개월도 채 되지 않아 순매출 1억 달러를 달성해 블록버스터 제품이 되었으며, 엘랑코가 보유한 반려동물 건강 분야 제품 중 가장 빠르게 블록버스터가 되었습니다. 이 제품은 6월 미국 수의과 병원에서의 광범위 제품 매출 기준으로 달러 기준 점유율 14%를 차지했습니다.
회사는 또한 매일 1회 투여하는 경구용 JAK 억제제인 Zenrelia를 EU와 영국에 출시했다고 발표했습니다. 이 제품은 전 세계적으로 이미 50만 마리 이상의 개를 치료했으며, 25개 센터에서 338마리의 개를 대상으로 한 연구에서 Apoquel과 비교해 열등하지 않음을 입증했습니다.
Elanco Animal Health (NYSE:ELAN) a annoncé des jalons importants pour deux produits clés destinés à la santé des animaux de compagnie. Credelio Quattro a atteint le statut de blockbuster avec 100 millions de dollars de ventes nettes en moins de huit mois, devenant le blockbuster le plus rapide d'Elanco dans la santé des animaux de compagnie. Le produit a obtenu une part de valeur de 14% sur les ventes à large spectre dans les cliniques vétérinaires américaines en juin.
La société a également lancé Zenrelia, un inhibiteur JAK oral à administration quotidienne pour le traitement de la dermatite allergique et atopique chez le chien, dans l'UE et en Grande-Bretagne. Le produit a déjà traité plus d’un demi-million de chiens dans le monde et a démontré une non-infériorité par rapport à Apoquel dans une étude menée sur 338 chiens dans 25 centres.
Elanco Animal Health (NYSE:ELAN) gab wichtige Meilensteine für zwei zentrale Produkte im Bereich Heimtiergesundheit bekannt. Credelio Quattro erreichte in weniger als acht Monaten den Blockbuster-Status mit 100 Millionen US-Dollar Nettoumsatz und wurde damit Elancos schnellster Blockbuster im Bereich Heimtiergesundheit. Das Produkt erzielte im Juni einen Dollar-Anteil von 14% am Umsatz mit breit wirksamen Produkten in US-tierärztlichen Kliniken.
Das Unternehmen kündigte außerdem die Einführung von Zenrelia an, einem einmal täglich oral zu verabreichenden JAK-Inhibitor zur Behandlung von allergischer und atopischer Dermatitis bei Hunden, in der EU und in Großbritannien. Das Produkt hat weltweit bereits über eine halbe Million Hunde behandelt und zeigte in einer Studie mit 338 Hunden an 25 Standorten Nicht-Unterlegenheit gegenüber Apoquel.
- Credelio Quattro reached $100 million blockbuster status in record time (less than 8 months)
- Credelio Quattro captured 14% dollar share in broad-spectrum sales at U.S. veterinary clinics
- Zenrelia successfully launched in multiple major markets including EU, UK, Brazil, Canada, Japan, and US
- Over half a million dogs treated with Zenrelia globally
- Geographic expansion planned for Credelio Quattro starting in 2026 with submissions in multiple countries
- None.
Insights
Elanco's Credelio Quattro achieved blockbuster status in record time, showcasing effective portfolio expansion strategy and strong market demand.
Elanco's announcement reveals impressive commercial execution with Credelio Quattro reaching the
The strategic portfolio development is particularly noteworthy—Credelio Quattro joins Experior as the second of six recently launched potential blockbusters to hit the
Meanwhile, Zenrelia's rollout across multiple international markets (EU, Great Britain, Brazil, Canada, Japan, and U.S.) indicates successful regulatory navigation and manufacturing scale-up. The non-inferiority study versus market incumbent Apoquel, published in a peer-reviewed journal, provides scientific validation that strengthens the product's competitive positioning. With "more than half a million dogs treated" globally, Zenrelia demonstrates meaningful commercial traction in the dermatology segment.
The planned geographic expansion of Credelio Quattro in 2026 to Australia, Canada, EU, UK, and Japan represents substantial growth potential, effectively multiplying the addressable market beyond the current single-geography success.
- Credelio Quattro marked
$100 million - Credelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the
$100 million - Zenrelia™ (ilunocitinib tablets) now in market in the European Union (EU) and
Great Britain
Credelio Quattro, Elanco's latest parasite innovation brought to market, became Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval, reaching blockbuster status of
"Credelio Quattro continues to break boundaries when it comes to offering veterinarians and pet owners parasite protection," said Bobby Modi, Executive Vice President,
Human and pet cases of tickborne disease, such as Lyme disease which is spread by the black-legged tick, are on the rise. According to the Companion Animal Parasite Council (CAPC), black-legged ticks are found across much of the eastern half of
"When I talk to veterinarians and pet owners, I hear they want something that's reliable, that's going to be easy to give and that's powerful against the different parasites: heartworms, ticks, and intestinal parasites including hookworms and tapeworms," said Dr. Lindsay Starkey, veterinarian and tenured Associate Professor of Parasitology at Oklahoma State University's College of Veterinary Medicine. "Credelio Quattro meets all of these expectations with its broad spectrum parasite control."
Credelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the blockbuster milestone of
Zenrelia Now in Market in EU and
Zenrelia, an effective, convenient, and safe once-daily oral JAK inhibitor, continues its launch progress globally, gaining approval from the
"Now we have a medication that is once a day right from the start. I think it will really help improve that owner, patient, pet bond, it will hopefully help reduce caregiver burden and will improve patient and carer quality of life as well," said Dr. Victoria Robinson BVM&S, BSc, CertAVP (VD), DipECVD, MRCVS, RCVS and European Specialist in Veterinary Dermatology. "Knowing what I currently know about Zenrelia, I am keen to use it in the clinic and start prescribing it."
This launch represents a pivotal milestone within the international canine dermatology market, offering a single daily dose for controlling pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs over 12 months of age. Zenrelia is now available in the European Union,
"Zenrelia joins our exciting, growing international pet health portfolio, including AdTab, Credelio Plus, Galliprant (grapiprant tablets) and others," said Ramiro Cabral, Executive Vice President, Elanco International. "We are very pleased with the results we are seeing in the global market, with more than half a million dogs treated with Zenrelia."
As part of the EU approval process, Elanco conducted a head-to-head non-inferiority study versus the marketplace incumbent, Apoquel. The randomized, double-blind study of 338 client-owned dogs with confirmed atopic dermatitis was conducted across 25 study sites in four countries. The study is published in a leading peer-reviewed, international journal, Veterinary Dermatology: https://doi.org/10.1111/vde.13319.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning expected regulatory approvals and commercial expansion plans. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, our ability to obtain regulatory approval of our products in different jurisdictions, the availability of adequate supply of products, and additional factors that could cause actual results to differ materially from forward-looking statements described in the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Indications for Zenrelia
Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age.
IMPORTANT SAFETY INFORMATION
See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia.
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.
Indications for Credelio Quattro
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.
Important Safety Information for Credelio Quattro
Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, ataxia, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro administration as it is not effective against adult D. immitis. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. For complete safety information, please see the Credelio Quattro product label or ask your veterinarian.
Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.dekker@elancoah.com
i Based on label comparison of the number of parasite types covered in an isoxazoline endectocide
ii Amblyomma americanum (lone star tick)
iii Based on time to statistical significance vs control in a head-to-head study. The study compared Credelio™ (lotilaner)—not Credelio Quattro™, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio™ (sarolaner, moxidectin, and pyrantel) and NexGard™ (afoxolaner).
View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-innovation-builds-momentum-credelio-quattro-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-reaches-blockbuster-status-302548581.html
SOURCE Elanco Animal Health
FAQ
How much revenue has Credelio Quattro generated for Elanco (NYSE:ELAN)?
What market share does Credelio Quattro have in U.S. veterinary clinics?
Where is Zenrelia currently available for pet owners?
How many parasites does Credelio Quattro protect against?
How many dogs have been treated with Zenrelia globally?
